![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
HT Schambye, SA Hjorth, J Weinstock and TW Schwartz
University Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.
His256 (HisVI:16) of transmembrane segment (TM)-VI of the rat angiotensin type 1 (AT1) receptor was targeted for mutagenesis to investigate its potential involvement in ligand binding. Substitution of His256 with alanine, phenylalanine, glutamine, or isoleucine did not affect the binding of either angiotensin II or nine different biphenylimidazole AT1 antagonists. In contrast, the binding affinity of the prototype imidazoleacrylic acid antagonist SKF-108,566 was reduced 15-fold by the exchange of His256 with alanine. Substitution of His256 with either isoleucine or phenylalanine yielded similar results, whereas a glutamine residue was able to substitute for His256, suggesting that the epsilon-nitrogen of His256 could be involved in the interaction with the imidazoleacrylic acid. To identify the chemical groups on SKF-108,566 that interact with His256 and with Asn295, a previously identified interaction point for nonpeptide antagonists located in TM-VII, we tested the binding of 15 analogs of SKF-108,566 in which different chemical moieties were systematically exchanged. The results indicated that the carboxyphenyl group of SKF-108,566 interacts with the imidazole side chain of His256. The data did not point to any particular contact group on the antagonist for Asn295. It is concluded that the imidazoleacrylic acid antagonists share some interactions in TM-VII of the AT1 receptor with the biphenylimidazole antagonists, but the binding of the imidazoleacrylic acid compounds is uniquely dependent on His256 in TM-VI, possibly through the carboxyphenyl moiety.
This article has been cited by other articles:
|
|
 |
|
  L. Oliveira, C. M. Costa-Neto, C. R. Nakaie, S. Schreier, S. I. Shimuta, and A. C. M. Paiva The Angiotensin II AT1 Receptor Structure-Activity Correlations in the Light of Rhodopsin Structure Physiol Rev, April 1, 2007; 87(2): 565 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Spivak, C. L. Beglan, B. K. Seidleck, L. D. Hirshbein, C. J. Blaschak, G. R. Uhl, and C. K. Surratt Naloxone Activation of µ-Opioid Receptors Mutated at a Histidine Residue Lining the Opioid Binding Cavity Mol. Pharmacol., December 1, 1997; 52(6): 983 - 992. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Phalipou, N. Cotte, E. Carnazzi, R. Seyer, E. Mahe, S. Jard, C. Barberis, and B. Mouillac Mapping Peptide-binding Domains of the Human V1a Vasopressin Receptor with a Photoactivatable Linear Peptide Antagonist J. Biol. Chem., October 17, 1997; 272(42): 26536 - 26544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Perlman, C. M. Costa-Neto, A. A. Miyakawa, H. T. Schambye, S. A. Hjorth, A. C. M. Paiva, R. A. Rivero, W. J. Greenlee, and T. W. Schwartz Dual Agonistic and Antagonistic Property of Nonpeptide Angiotensin AT1 Ligands: Susceptibility to Receptor Mutations Mol. Pharmacol., February 1, 1997; 51(2): 301 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Noda, Y. Saad, and S. S. Karnik Interaction of Phe^8 of Angiotensin II with Lys[IMAGE] and His[IMAGE] of AT(1) Receptor in Agonist Activation J. Biol. Chem., December 1, 1995; 270(48): 28511 - 28514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Marie, E. Richard, D. Pruneau, J.-L. Paquet, C. Siatka, R. Larguier, C. Ponce, P. Vassault, T. Groblewski, B. Maigret, et al. Control of Conformational Equilibria in the Human B2 Bradykinin Receptor. MODELING OF NONPEPTIDIC LIGAND ACTION AND COMPARISON TO THE RHODOPSIN STRUCTURE J. Biol. Chem., October 26, 2001; 276(44): 41100 - 41111. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
